Immunopriming of tumor infiltrating lymphocytes with neoadjuvant cyclophosphamide.
Tumor infiltrating lymphocytes (TIL) are increasingly employed in immunotherapy protocols. When modified and expanded they can be utilized in new therapeutic protocols. TIL augmentation can be in vitro and in vivo. The purpose of this article is to review the various methods of TIL augmentation and report our experience with a neoadjuvant technique of cyclophosphamide immunopriming of TILs.
Guinan
P
P
Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, Illinois.
Shaw
M
M
Rubenstein
M
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D002452:Cell Count / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology*; D007372:Interferons / Q000494:pharmacology; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects*; D009362:Neoplasm Metastasis / Q000276:immunology; D051381:Rats; D011919:Rats, Inbred Strains; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*
D000276:Adjuvants, Immunologic; D003520:Cyclophosphamide; D007372:Interferons